Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: Comparison with SHU9119

Neuropeptides

Volumn 33, Issue 3, 1999, Pages 191-196

  Schioth H B ^a   Muceniece, R ^a,b   Mutulis, F ^a,b   Bouifrouri, A A ^a   Mutule, I ^a,b   Wikberg, J E S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; MELANOCORTIN RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; SH 019; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

EID: 0344035658     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.1999.0760     Document Type: Article

References (26)

1. Chhajlani V., Wikberg J. E. S. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 309:1992;417-420.
2. Mountjoy K. G., Robbins L. S., Mortrud M. T., Cone R. D. The cloning of a family of genes that encode the melanocortin receptors. Science. 257:1992;1248-1251.
3. Gantz I., Konda Y., Tashiro T. Molecular cloning of a novel melanocortin receptor. J Biol Chem. 268:1993;8246-8250.
4. Gantz I., Miwa H., Konda Y. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem. 268:1993;15174-15179.
5. Chhajlani V., Muceniece R., Wikberg J. E. S. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun. 195:1993;866-873.
6. Lipton J. M., Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today. 18:1997;140-145.
7. Huszar D., Lynch C. A., Fairchild-Huntress V. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141.
8. Chen W., Kelly M. A., Opitz-Araya X., Thomas R. E., Low M. J., Cone R. D. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 91:1997;789-798.
9. Schiöth H. B., Wikberg J. E. S., Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol Mol Pharm Sect. 288:1995;311-317.
10. Schiöth H. B., Muceniece R., Wikberg J. E. S. Characterisation of melanocortin 4 receptor by radioligand binding analysis. Pharmacol & Toxicol. 79:1996;161-165.
11. Schiöth H. B., Muceniece R., Larsson M., Wikberg J. E. S. The melanocortin 1, 3, 4 or 5 receptors do not have a binding epitope for ACTH beyond the sequence of a-MSH. J Endocrinology. 155:1997;73-78.
12. 2with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 38:1995;3454-3461.
13. Schiöth H. B., Mutulis F., Muceniece R., Prusis P., Wikberg J. E. S. Discovery of novel melanocortin 4 receptor selective MSH analogues. Brit J Pharmacology. 124:1998;75-82.
14. Kask A., Rägo L., Mutulis F., Wikberg J. E. S., Schiöth H. B. Selective melanocortin 4 receptor antagonist (HS014) increases food intake in free-feeding rats. Biochem Biophys Res Commun. 245:1998;90-93.
15. Kask A., Rägo L., Korrovits P., Wikberg J. E. S., Schiöth H. B. Evidence that the orexigenic effects of melanocortin 4 receptor antagonist are mediated by NPY. Biochem Biophys Res Commun. 248:1998;245-249.
16. Seeley R. J., Yagaloff K. A., Fisher S. L. Melanocortin receptors in leptin effects. Nature. 390:1997;349.
17. Fan W., Boston B. A., Kesterson R. A., Hruby V. J., Cone R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 385:1997;165-168.
18. Vergoni A. V., Bertolini A., Mutulis F., Wikberg J. E. S., Schiöth H. B. A differential influence of a selective melanocortin 4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats. Eur J Pharmacol. 362:1998;95-101.
19. Li S. J., Varga K., Archer P. Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones. Neurosci. 16:1996;5182-5188.
20. Ni X. P., Kesterson R. A., Sharma S. D. Prevention of reflex natriuresis after acute unilateral nephrectomy by melanocortin receptor antagonists. Am J Physiol. 274:1998;R931-938.
21. Klusa V., Svirskis S., Opmane B. Evaluation of behavioural effects of neural melanocortin receptors antagonists injected ICV and in VTA in rats. Neuropeptides. 32:1998;573-580.
22. Von Frijtag J. C., Croiset G., Gispen W. H., Adan R. A., Wiegant V. M. The role of central melanocortin receptors in the activation of the hypothalamus-pituitary-adrenal-axis and the induction of excessive grooming. Br J Pharmacol. 123:1998;1503-1508.
23. Huang Q. H., Hruby V. J., Tatro J. B. Systemic alpha-MSH suppresses LPS fever via central melanocortin receptors independently of its suppression of corticosterone and IL-6 release. Am J Physiol. 275:1998;R524-530.
24. Nordstedt C., Fredholm B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Analytical Chemistry. 189:1990;231-234.
25. 7] substituted MSH analogues for the melanocortin receptors. Peptides. 18:1997;1009-1013.
26. Schiöth H. B., Mutulis F., Muceniece R., Prusis P., Wikberg J. E. S. Selective properties of C-and N-terminals and core residues of the melanocyte-stimulating hormone on binding to the human melanocortin receptor subtypes. Eur J Pharmacol. 349:1998;359-366.